Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4620
Source ID: NCT00461006
Associated Drug: Actos
Title: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: Actos|DRUG: aleglitazar
Outcome Measures: Primary: Relative change from baseline in glomerular filtration rate, 26 weeks | Secondary: Relative change from baseline in estimated renal plasma flow (ERPF) and urine albumin-creatinine ratio (UACR), 26 weeks|Absolute change in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and fasting plasma insulin (FPI)., End of treatment|Adverse events (AEs), laboratory parameters., Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 176
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2007-06
Completion Date: 2008-09
Results First Posted:
Last Update Posted: 2016-08-01
Locations: Peoria, Arizona, 85381, United States|Jonesboro, Arkansas, 72401, United States|Fresno, California, 93720, United States|Los Gatos, California, 95032, United States|Mission Viejo, California, 92691, United States|Jacksonville, Florida, 32216-4313, United States|Omaha, Nebraska, 68131, United States|Charlotte, North Carolina, 28211, United States|Marion, Ohio, 43302, United States|Altoona, Pennsylvania, 16602, United States|Arlington, Texas, 76014, United States|Arlington, Texas, 76017, United States|Dallas, Texas, 75231, United States|Midland, Texas, 79707, United States|San Antonio, Texas, 78284, United States|Norfolk, Virginia, 23510, United States|Chihuahua, 31238, Mexico|Chihuahua, 31328, Mexico|Hermosillo, 83067, Mexico|Metepec, EMEX52140, Mexico|Mexico City, 11650, Mexico|Mexico City, 14000, Mexico|Mexico City, 14050, Mexico|Monterrey, 64000, Mexico|Zapopan, 45200, Mexico|Manati, 00674, Puerto Rico|Ponce, 00717-322, Puerto Rico|Toa Baja, 00949, Puerto Rico|Moscow, 109472, Russian Federation|Moscow, 125101, Russian Federation|Moscow, 127299, Russian Federation|Moscow, 127486, Russian Federation|Moscow, 129110, Russian Federation|Saratov, 410038, Russian Federation|St Petersburg, 191025, Russian Federation|St Petersburg, 197198, Russian Federation|St Petersburg, 198205, Russian Federation|St. Petersburg, 199106, Russian Federation|Tumen, 625023, Russian Federation|Yaroslavl, 150062, Russian Federation|Dnipropetrovs'k, 49005, Ukraine|Dnipropetrovs'k, 49060, Ukraine|Donetsk, 83003, Ukraine|Donetsk, 83114, Ukraine|Kharkiv, 61039, Ukraine|Kharkov, 61178, Ukraine|Kiev, 02091, Ukraine|Kiev, 2091, Ukraine|Kiev, 2125, Ukraine|Lugnansk, 91045, Ukraine|Poltava, 36024, Ukraine|Ternopil, 46002, Ukraine
URL: https://clinicaltrials.gov/show/NCT00461006

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D336 Pioglitazone small molecule DB01132 Details